JAMA Dermatology —The Year in Review, 2025

• by Kanade Shinkai

• May 1, 2026

Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1)

• by Yoshio Nakamura, Naoya Yamazaki, Kenjiro Namikawa, Hiroshi Uchi, Shoichiro Mori, Mariko Ogawa-Momohara, Taku Fujimura, Tatsuya Takenouchi, Mana Kurimoto, Yuki Yamamoto, Atsushi Otsuka, Kenji Kabashima, Takayuki Fusumae, Ikuko Hirai, Keiji Tanese, Yasuko Saito, Masayuki Amagai, Ryo Takemura, Yasunori Sato, Takeru Funakoshi

• March 4, 2026

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

• by Arthur Allen

• May 15, 2026

• 9 min

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

• by Kerri Miller

• April 6, 2026

• 2 min